Rare variants in the GABA


Journal

Molecular genetics & genomic medicine
ISSN: 2324-9269
Titre abrégé: Mol Genet Genomic Med
Pays: United States
ID NLM: 101603758

Informations de publication

Date de publication:
09 2020
Historique:
received: 21 02 2020
revised: 29 05 2020
accepted: 31 05 2020
pubmed: 27 6 2020
medline: 28 5 2021
entrez: 27 6 2020
Statut: ppublish

Résumé

Epilepsy belongs to a group of chronic and highly heterogeneous brain disorders. Many types of epilepsy and epileptic syndromes are caused by genetic factors. The neural amino acid y-aminobutyric acid (GABA) is a major inhibitory neurotransmitter in the mammalian central nervous system. It regulates activity of channel pores by binding to transmembrane GABA-receptors (GABRs). The GABRs are heteropentamers assembled from different receptor subunits (α1-6, β1-3, γ1-3, δ, ε, θ, π, and ρ1-3). Several epileptic disorders are caused by mutations in genes encoding single GABRs. We applied trio- and single-whole exome sequencing to search for genetic sequence variants associated with a wide range of epileptic phenotypes accompanied by intellectual disability and/or global developmental delay in the investigated patients. We identified four hemizygous sequence variants in the GABA Our clinical and molecular genetic findings suggest that GABRE is a likely candidate gene for epilepsy. Nevertheless, functional studies are necessary to better understand pathogenicity of the GABRE-mutations and their associations with epileptic phenotypes.

Sections du résumé

BACKGROUND
Epilepsy belongs to a group of chronic and highly heterogeneous brain disorders. Many types of epilepsy and epileptic syndromes are caused by genetic factors. The neural amino acid y-aminobutyric acid (GABA) is a major inhibitory neurotransmitter in the mammalian central nervous system. It regulates activity of channel pores by binding to transmembrane GABA-receptors (GABRs). The GABRs are heteropentamers assembled from different receptor subunits (α1-6, β1-3, γ1-3, δ, ε, θ, π, and ρ1-3). Several epileptic disorders are caused by mutations in genes encoding single GABRs.
METHODS
We applied trio- and single-whole exome sequencing to search for genetic sequence variants associated with a wide range of epileptic phenotypes accompanied by intellectual disability and/or global developmental delay in the investigated patients.
RESULTS
We identified four hemizygous sequence variants in the GABA
CONCLUSION
Our clinical and molecular genetic findings suggest that GABRE is a likely candidate gene for epilepsy. Nevertheless, functional studies are necessary to better understand pathogenicity of the GABRE-mutations and their associations with epileptic phenotypes.

Identifiants

pubmed: 32588540
doi: 10.1002/mgg3.1388
pmc: PMC7507344
doi:

Substances chimiques

Codon, Initiator 0
Codon, Nonsense 0
GABRE protein, human 0
Receptors, GABA-A 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1388

Informations de copyright

© 2020 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.

Références

PLoS One. 2018 Mar 8;13(3):e0193599
pubmed: 29518120
J Formos Med Assoc. 2017 Oct;116(10):736-741
pubmed: 28648375
Nat Rev Neurosci. 2001 Apr;2(4):240-50
pubmed: 11283747
J Neurosci. 1998 Aug 15;18(16):6378-87
pubmed: 9698329
J Physiol. 2001 Nov 15;537(Pt 1):101-13
pubmed: 11711565
Nat Biotechnol. 2009 Feb;27(2):182-9
pubmed: 19182786
Int Rev Cytol. 2002;213:1-47
pubmed: 11837891
Nature. 1997 Feb 27;385(6619):820-3
pubmed: 9039914
Neurology. 2014 Apr 8;82(14):1245-53
pubmed: 24623842
Epilepsia. 2014 Apr;55(4):475-82
pubmed: 24730690
Nat Rev Neurosci. 2005 Mar;6(3):215-29
pubmed: 15738957
Trends Pharmacol Sci. 2000 Nov;21(11):411-3
pubmed: 11121567
Curr Opin Neurol. 2019 Apr;32(2):183-190
pubmed: 30664068
Mol Cell Neurosci. 2008 Mar;37(3):610-21
pubmed: 18206389
Pharmacol Biochem Behav. 2013 Sep;110:174-84
pubmed: 23872369
J Med Genet. 2017 Mar;54(3):202-211
pubmed: 27789573
Ann Neurol. 2019 Dec;86(6):821-831
pubmed: 31618474
J Neurosci. 1996 Sep 1;16(17):5415-24
pubmed: 8757254
Neurology. 2016 Sep 13;87(11):1140-51
pubmed: 27521439
PLoS One. 2016 Nov 21;11(11):e0167264
pubmed: 27870904
Mol Genet Genomic Med. 2020 Sep;8(9):e1388
pubmed: 32588540
Neurotherapeutics. 2014 Oct;11(4):796-806
pubmed: 25266964
Neurol Neurochir Pol. 2010 May-Jun;44(3):285-90
pubmed: 20648993
Science. 1964 Apr 10;144(3615):193-4
pubmed: 14107481
Proc Natl Acad Sci U S A. 1980 Mar;77(3):1496-500
pubmed: 6929499
J Neurosci. 1997 Apr 15;17(8):2728-37
pubmed: 9092594
Sci Rep. 2017 Jan 11;7:40319
pubmed: 28074849
Hum Mutat. 2019 Aug;40(8):1030-1038
pubmed: 31116477
Ann Neurol. 2016 May;79(5):806-825
pubmed: 26950270
Epilepsia. 2005;46 Suppl 1:38-43
pubmed: 15816978
Curr Opin Neurol. 2017 Apr;30(2):193-199
pubmed: 28212175
Brain. 2019 Jul 1;142(7):1938-1954
pubmed: 31056671
PLoS One. 2016 Sep 13;11(9):e0162883
pubmed: 27622563
Nat Genet. 2002 Jun;31(2):184-9
pubmed: 11992121
Nat Chem Biol. 2012 Mar 25;8(5):455-64
pubmed: 22446838
Seizure. 2017 Jan;44:11-20
pubmed: 28007376
Annu Rev Neurosci. 1994;17:569-602
pubmed: 7516126
Epilepsy Res. 2017 Nov;137:9-18
pubmed: 28865303
Arch Neurol. 1967 Feb;16(2):194-202
pubmed: 6018049
J Neurosci. 1994 Jan;14(1):29-38
pubmed: 8283236
Neurology. 2017 Jan 31;88(5):483-492
pubmed: 28053010
Pharmacol Rev. 2018 Jan;70(1):142-173
pubmed: 29263209
Brain. 2017 Jan;140(1):49-67
pubmed: 27864268
Epilepsia. 2010 Apr;51(4):676-85
pubmed: 20196795
Brain. 2018 Aug 1;141(8):2392-2405
pubmed: 29961870
Curr Opin Neurol. 2013 Apr;26(2):163-7
pubmed: 23406910
J Neurosci. 2005 Nov 9;25(45):10462-8
pubmed: 16280584
BMC Pharmacol. 2006 Jan 13;6:1
pubmed: 16412217
J Neurosci. 1994 Nov;14(11 Pt 2):7077-86
pubmed: 7525894
Indian J Med Res. 2016 Nov;144(5):657-660
pubmed: 28361817
Neuropharmacology. 2003 Jun;44(8):994-1002
pubmed: 12763092
Ann Clin Transl Neurol. 2019 Nov;6(11):2317-2322
pubmed: 31568673
Nat Commun. 2018 Sep 28;9(1):3972
pubmed: 30266951
Mol Pharmacol. 1999 Jan;55(1):168-78
pubmed: 9882711
Epilepsia. 2016 Apr;57(4):566-73
pubmed: 26918889

Auteurs

Fenja Markus (F)

Junior Research Group, Genetics of Childhood Brain Malformations, Faculty VI-School of Medicine and Health Sciences, University of Oldenburg, Oldenburg, Germany.
Human Genetics, Faculty VI-School of Medicine and Health Sciences, University of Oldenburg, Oldenburg, Germany.

Chloé Angelini (C)

Service de Génétique médicale, CHU de Bordeaux, Bordeaux, France.

Aurelien Trimouille (A)

Service de Génétique médicale, CHU de Bordeaux, Bordeaux, France.

Gabrielle Rudolf (G)

CNRS U7104, INSERM U1258, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France.
Service de Neurologie, Centre de Références des Maladies Neurogénétique Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Gaetan Lesca (G)

Genetics department, Lyon University Hospital and University of Lyon, Lyon, France.

Cyril Goizet (C)

Service de Génétique médicale, CHU de Bordeaux, Bordeaux, France.
CNRS U7104, INSERM U1258, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France.

Eulalie Lasseaux (E)

Service de Génétique médicale, CHU de Bordeaux, Bordeaux, France.

Benoit Arveiler (B)

Service de Génétique médicale, CHU de Bordeaux, Bordeaux, France.

Marjon van Slegtenhorst (M)

Department of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

Alice S Brooks (AS)

Department of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

Rami Abou Jamra (R)

Institute of Human Genetics, University Medical Center Leipzig, Leipzig, Germany.

Georg-Christoph Korenke (GC)

Department of Neuropediatrics, University Children's Hospital, Oldenburg, Germany.

John Neidhardt (J)

Human Genetics, Faculty VI-School of Medicine and Health Sciences, University of Oldenburg, Oldenburg, Germany.
Research Center Neurosensory Science, University of Oldenburg, Oldenburg, Germany.

Marta Owczarek-Lipska (M)

Junior Research Group, Genetics of Childhood Brain Malformations, Faculty VI-School of Medicine and Health Sciences, University of Oldenburg, Oldenburg, Germany.
Human Genetics, Faculty VI-School of Medicine and Health Sciences, University of Oldenburg, Oldenburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH